

Supporting Information

For

Iodine-promoted Cyclization of *N*-propynyl amides and *N*-allyl amides *via* Sulfonylation and Sulfenylation

Gopal Chandru Senadi,^{‡,a} Bing-Chun Guo,^{‡,a} Wan-Ping Hu,^b and Jeh-Jeng Wang^{a*}

^a*Department of Medicinal and Applied Chemistry, Kaohsiung Medical University, No. 100, Shih-Chuan 1st Rd, Sanmin District, Kaohsiung City, 807 (Taiwan).*

^b*Department of Biotechnology, Kaohsiung Medical University, No. 100, Shih-Chuan 1st Rd, Sanmin District, Kaohsiung City, 807 (Taiwan).*

[‡]*These two authors contributed equally.*

E-mail: jjwang@kmu.edu.tw.


Table of Contents

1) General Information	S3
2) Optimization of reaction conditions	S4
3) General Experimental Procedures and Spectral Characterization	S5-S17
4) CCDC numbers	S17-S19
5) X-ray Crystallography Data	S20-S28
6) References	S29
7) Copies of ^1H , ^{13}C and DEPT spectra	S30-S167

1) General Information

^1H , ^{13}C and DEPT NMR spectra were recorded on a 400 MHz Varian Unity Plus or Varian Mercury plus spectrometer or JEOL 400 MHz. The chemical shift (δ) values are reported in parts per million (ppm), and the coupling constants (J) are given in Hz. The spectra were recorded using CDCl_3 as a solvent. ^1H NMR chemical shifts are referenced to tetramethylsilane (TMS) (0 ppm). ^{13}C NMR was referenced to CDCl_3 (77.0 ppm). The abbreviations used are as follows: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublet; ddd, doublet of doublet of doublet; dt, doublet of triplets; td, triplet of doublet; m, multiplet. Mass spectra and high-resolution mass spectra (HRMS) was measured using the ESI (FT-MS solariX) at National Sun Yat-Sen University, Kaohsiung, Taiwan or LTQ Orbitrap XL (Thermo Fischer Scientific) at National Chung Hsing University. All IR spectra were obtained as neat films with a Perkin-Elmer Model 2000 FT-IR SYSTEM and selected absorbance are reported in cm^{-1} . Melting points were determined on an EZ-Melt (Automated melting point apparatus). All products reported showed ^1H NMR spectra in agreement with the assigned structures. Reaction progress and product mixtures were routinely monitored by TLC using Merck TLC aluminum sheets (silica gel 60 F254). Column chromatography was carried out with 230–400 mesh silica gel 60 (Merck)/neutral alumina and a mixture of hexane/ethyl acetate or hexane as an eluent.

2) Table S1. Optimization of the sulfenylation reaction conditions.^a




entry	I source (X equiv)	solvent	time (h)	yield (%)
1	I ₂ (0.1)	1,2-dichloroethane	48	<10 ^c
2	I ₂ (0.1)	1,4-dioxane	48	<5 ^c
3	I ₂ (0.1)	DMSO	48	trace ^c
4	I ₂ (0.1)	DMF	48	trace ^c
5	I ₂ (0.1)	CH ₃ CN	48	trace ^c
6	I ₂ (0.1)	Toluene	48	15 ^c
7	I ₂ (0.5)	Toluene	24	32 ^b
8 ^d	I ₂ (0.5)	Toluene	24	24 ^b
9	I ₂ (0.75)	Toluene	24	48 ^b
10	I ₂ (1.0)	Toluene	5	65 ^c
11	I ₂ (1.0)	1,2-dichloroethane	24	53 ^b
12	KI (1.0)	Toluene	24	7 ^b
13	NaI (1.0)	Toluene	24	7 ^b
14	TBAI (1.0)	Toluene	24	4 ^b
15	NIS (1.0)	Toluene	24	5 ^b
16	NBS (1.0)	Toluene	24	12 ^b
17 ^e	I ₂ (2.0)	Toluene	24	<10 ^c
18	KI (2.0)	Toluene	24	4 ^b
19	NAI (2.0)	Toluene	24	4 ^b
20	TBAI (2.0)	Toluene	24	5 ^b
21	-	Toluene	3	0 ^c

^a Reaction conditions: **5a** (1.0 mmol), **2a** (1.5 mmol), iodo source (X equiv), solvent (2.0 mL) at 120 °C for 5 h. ^b Determined by GC-MS analysis. ^c Isolated yields. ^d Under O₂. ^e 5-(iodomethyl)-2-phenyl-4,5-dihydrooxazole was isolated as a major product. ^f In the absence of iodine, *S*-(*p*-tolyl) 4-methylbenzenesulfonothioate was isolated as major product and 1,2-di-*p*-tolyl disulfane was isolated as minor product with recovery of **5a**.

3) General Experimental Procedures and Spectral Characterization

The starting materials **1(a-o)**¹⁻⁹ and **5(a-c)**¹⁰⁻¹² were prepared according to the previously reported literatures.¹⁻⁹ The spectra data complies to the reported literature values.¹⁻⁹


N-(Prop-2-yn-1-yl)benzamide (1a).¹ ¹H NMR (400 MHz, CDCl₃) δ 7.84 – 7.75 (m, 2H), 7.49 (d, *J* = 7.4



Hz, 1H), 7.45 – 7.36 (m, 2H), 6.67 (s, 1H), 4.24 (dd, *J* = 5.3, 2.6 Hz, 2H), 2.27 (t, *J* = 2.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 167.18, 133.65, 131.70, 128.52, 127.01,

79.50, 71.71, 29.69.


4-Methyl-N-(prop-2-yn-1-yl)benzamide (1b).² ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, *J* = 8.2 Hz, 2H),



7.25 – 7.19 (m, 2H), 6.55 (s, 1H), 4.23 (dd, *J* = 5.2, 2.6 Hz, 2H), 2.39 (s, 3H), 2.27 (d, *J* = 2.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 167.08, 142.17, 130.82, 129.18,

127.01, 79.63, 71.64, 29.64, 21.40.


4-Methoxy-N-(prop-2-yn-1-yl)benzamide (1c).¹ ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, *J* = 8.9 Hz, 2H),



6.91 (d, *J* = 8.9 Hz, 2H), 6.42 (s, 1H), 4.23 (dd, *J* = 5.2, 2.6 Hz, 2H), 3.84 (s, 3H), 2.27 (t, *J* = 2.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 166.64, 162.35, 128.86,

125.97, 113.74, 79.71, 71.65, 55.37, 29.67.


3-Methoxy-N-(prop-2-yn-1-yl)benzamide (1d).³ ¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.35 (m, 1H), 7.31



(dd, *J* = 4.2, 2.0 Hz, 2H), 7.08 – 6.98 (m, 1H), 6.68 (s, 1H), 4.23 (dd, *J* = 5.3, 2.6 Hz, 2H), 3.82 (s, 3H), 2.27 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 167.02, 159.72,

135.11, 129.51, 118.80, 117.91, 112.36, 79.46, 71.70, 55.35, 29.70.


4-Fluoro-N-(prop-2-yn-1-yl)benzamide (1e).³ ¹H NMR (400 MHz, CDCl₃) δ 7.86 – 7.78 (m, 2H), 7.10 (dd,



J = 9.6, 7.7 Hz, 2H), 6.67 (s, 1H), 4.23 (dd, *J* = 5.3, 2.6 Hz, 2H), 2.28 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 166.12, 164.87 (d, *J* = 260.0 Hz), 163.57, 129.42 (d, *J* =

8.8 Hz), 115.59 (d, *J* = 22.0 Hz), 115.48, 79.37, 71.80, 29.76.


4-Chloro-N-(prop-2-yn-1-yl)benzamide (1f).³ ¹H NMR (400 MHz, CDCl₃) δ 7.77 – 7.69 (m, 2H), 7.45 –



7.37 (m, 2H), 6.46 (s, 1H), 4.24 (dd, *J* = 5.2, 2.6 Hz, 2H), 2.29 (t, *J* = 2.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 166.08, 138.07, 132.05, 128.87, 128.46, 79.23,

72.01, 29.84.


4-Bromo-*N*-(prop-2-yn-1-yl)benzamide (1g).⁴ ¹H NMR (400 MHz, CDCl₃) δ 7.69 – 7.63 (m, 2H), 7.60 –



7.54 (m, 2H), 6.43 (s, 1H), 4.24 (dd, *J* = 5.2, 2.6 Hz, 2H), 2.29 (t, *J* = 2.6 Hz, 1H);
¹³C NMR (100 MHz, CDCl₃) δ 166.17, 132.51, 131.85, 128.62, 126.54, 79.21,

72.04, 29.84.


4-Iodo-*N*-(prop-2-yn-1-yl)benzamide (1h).⁸ ¹H NMR (400 MHz, CDCl₃) δ 7.83 – 7.75 (m, 2H), 7.54 –



7.46 (m, 2H), 6.33 (s, 1H), 4.24 (dd, *J* = 5.2, 2.6 Hz, 2H), 2.29 (t, *J* = 2.6 Hz, 1H);
¹³C NMR (100 MHz, CDCl₃) δ 166.30, 137.85, 133.07, 128.57, 98.86, 79.18,

72.10, 29.85.


***N*-(Prop-2-yn-1-yl)-4-(trifluoromethyl)benzamide (1i).**⁵ ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, *J* = 8.1 Hz,



2H), 7.69 (d, *J* = 8.2 Hz, 2H), 6.67 (s, 1H), 4.27 (dd, *J* = 5.2, 2.6 Hz, 2H), 2.30 (t,
J = 2.5 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 165.08, 139.20, 133.50 (d, *J*_{C,F} =

33.0 Hz), 131.00, 128.30, 125.64 (q, *J*_{C,F} = 3.7 Hz), 123.56 (d, *J*_{C,F} = 270.0 Hz), 122.20, 72.41, 45.79, 30.08.


4-Nitro-*N*-(prop-2-yn-1-yl)benzamide (1j).¹ ¹H NMR (400 MHz, CDCl₃) δ 8.30 (t, *J* = 7.2 Hz, 2H), 7.98



(d, *J* = 8.7 Hz, 2H), 6.56 (s, 1H), 4.34 – 4.25 (m, 2H), 2.33 (s, 1H); ¹³C NMR
(100 MHz, CDCl₃) δ 165.08, 139.20, 131.00, 128.30, 123.87, 123.46, 78.80,

72.41, 30.08.


***N*-(Prop-2-yn-1-yl)decanamide (1k).**⁶ ¹H NMR (400 MHz, CDCl₃) δ 5.86 (s, 1H), 4.05 (dd, *J* = 5.2, 2.6 Hz,



2H), 2.24 – 2.17 (m, 3H), 1.68 – 1.59 (m, 2H), 1.35 – 1.22 (m, 13H), 0.88
(t, *J* = 6.9 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.82, 79.66, 71.40,

36.42, 31.81, 29.24, 25.53, 22.61, 14.05.


5-Nitro-*N*-(prop-2-yn-1-yl)furan-2-carboxamide (1l).⁷ ¹H NMR (400 MHz, CDCl₃) δ 7.38 (d, *J* = 3.8 Hz,



1H), 7.31 (d, *J* = 3.8 Hz, 1H), 6.92 (s, 1H), 4.27 (dd, *J* = 5.5, 2.6 Hz, 3H), 2.33
(t, *J* = 2.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 155.85, 147.36, 116.43,

112.34, 78.19, 72.53, 29.24.


4-Chloro-*N*-(3-phenylprop-2-yn-1-yl)benzamide (1m). The compound was prepared by reported literature



protocol.⁹ ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, *J* = 8.7 Hz, 2H), 7.48 – 7.36 (m,
4H), 7.37 – 7.27 (m, 3H), 6.50 (s, 1H), 4.47 (d, *J* = 5.1 Hz, 2H); ¹³C NMR (100


MHz, CDCl₃) δ 166.07, 138.02, 132.21, 131.73, 131.47, 128.86, 128.45 (t, $J = 11.9$ Hz), 122.36, 84.41, 83.85, 30.73; HRMS (ESI) calcd for C₁₆H₁₃NOCl [M+H]⁺: 270.0680 found 270.0677.

***N*-(2-Methylbut-3-yn-2-yl)benzamide (1n)**.² ¹H NMR (400 MHz, CDCl₃) δ 7.78 – 7.74 (m, 2H), 7.52 –



7.39 (m, 3H), 6.26 (s, 1H), 2.39 (s, 1H), 1.77 (s, 7H). ¹³C NMR (100 MHz, CDCl₃) δ 166.44, 134.79, 131.45, 128.48, 126.84, 87.12, 69.34, 47.99, 28.97.

***N*-(1-Ethynylcyclohexyl)benzamide (1o)**.² ¹H NMR (400 MHz, CDCl₃) δ 7.80 – 7.73 (m, 2H), 7.52 – 7.45




(m, 1H), 7.42 (ddd, $J = 8.3, 4.4, 1.0$ Hz, 2H), 6.14 (s, 1H), 2.45 (s, 1H), 2.28 – 2.19 (m, 3H), 2.00 – 1.91 (m, 2H), 1.76 – 1.58 (m, 6H), 1.35 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 166.30, 134.98, 131.39, 128.47, 126.99 – 126.71, 85.43, 71.48, 52.03, 36.86,

25.21, 22.47.

General Procedure (A) for the Preparation of Sulfonylated Oxazoles


Preparation of 2-Phenyl-5-(tosylmethyl)oxazole (4aa).



To a stirred solution of *N*-propynyl benzamide **1a** (160 mg, 1.0 equiv) in acetonitrile (2.0 mL) was added tosylhydrazide **2a** (372 mg, 2.0 equiv), TBHP solution 70% in H₂O (258 μ L, 2.0 equiv) and iodine (128 mg, 50 mol %). The reaction mixture was heated to 90 °C. The completion of reaction was monitored by TLC chromatography. After completion, the reaction mixture was cooled to room temperature and added 1 mL of THF followed by the addition of DBU (301 μ L, 2.0 equiv). The completion of the reaction was monitored by TLC chromatography. After the completion, the reaction was diluted with 10 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was then given brine wash (2X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to get the crude compound. The obtained crude was then purified using column chromatography by eluting from hexane to 20% ethyl acetate/hexane to afford pure 2-Phenyl-5-(tosylmethyl)oxazole **4aa** as a light yellow solid (212 mg, 70%); mp 129.3~131.3 °C; IR (neat)_{vmax}: 1596, 1543, 1482, 1322, 1153, 989, 714, 691 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.78 (dd, $J =$

8.0, 1.7 Hz, 2H), 7.60 (d, $J = 8.3$ Hz, 2H), 7.41 – 7.32 (m, 3H), 7.23 (dd, $J = 8.5, 0.6$ Hz, 2H), 6.97 (s, 1H), 4.43 (d, $J = 0.7$ Hz, 2H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 162.76, 145.47, 140.41, 134.89, 130.94, 129.94, 129.51, 128.73, 126.52, 53.87, 21.66; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{NO}_3\text{S}$ $[\text{M}+\text{H}]^+$: 313.0845 found 313.0843.


2-Phenyl-5-((phenylsulfonyl)methyl)oxazole (4ab). Following the general procedure (A) on a 1.0 mmol



scale, giving the compound as a light brown solid (263 mg, 88%); mp 103.5~105.5 °C; IR (neat) $_{\text{vmax}}$: 1607, 1546, 1482, 1448, 1321, 1274, 1158, 1137, 1085, 989, 855, 776, 757 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3)

δ 7.89 – 7.78 (m, 4H), 7.65 (dd, $J = 11.8, 4.3$ Hz, 1H), 7.53 (t, $J = 7.8$ Hz, 2H), 7.44 (dd, $J = 8.2, 6.1$ Hz, 3H), 7.05 (s, 1H), 4.53 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 137.83, 134.23, 130.82, 129.72, 129.25, 128.66, 126.36, 53.74; HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{14}\text{NO}_3\text{S}$ $[\text{M}+\text{H}]^+$: 300.0688 found 300.0687.


5-(((4-Methoxyphenyl)sulfonyl)methyl)-2-phenyloxazole (4ac). Following the general procedure (A) on a



1.0 mmol scale, giving the compound as a yellow solid (312 mg, 95%); mp 140.1~142.1 °C; IR (neat) $_{\text{vmax}}$: 1595, 1545, 1496, 1324, 1262, 1149, 1078, 1024, 989, 836, 715 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.79 (dd,

$J = 7.6, 2.0$ Hz, 2H), 7.63 (d, $J = 9.0$ Hz, 2H), 7.44 – 7.32 (m, 3H), 6.97 (s, 1H), 6.88 (d, $J = 9.0$ Hz, 2H), 4.42 (s, 2H), 3.74 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.13, 162.64, 140.52, 130.79, 129.46, 129.17, 128.73, 126.60, 126.35, 114.39, 55.65, 53.94; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{NO}_4\text{S}$ $[\text{M}+\text{H}]^+$: 330.0794 found 330.0792.


5-(((4-Fluorophenyl)sulfonyl)methyl)-2-phenyloxazole (4ad). Following the general procedure (A) on a



1.0 mmol scale, giving the compound as a yellow solid (247 mg, 78%); mp 157.5~159.5 °C; IR (neat) $_{\text{vmax}}$: 1591, 1545, 1492, 1449, 1324, 1292, 1273, 1151, 988, 838, 787, 714 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ

7.84 (ddd, $J = 13.9, 8.2, 3.3$ Hz, 4H), 7.45 (dd, $J = 5.7, 3.7$ Hz, 3H), 7.20 (t, $J = 8.5$ Hz, 2H), 7.07 (s, 1H), 4.53 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.37, 166.09 (d, $J = 256.0$ Hz), 164.81, 139.92, 131.49 (d, $J = 9.7$ Hz), 129.83, 128.80, 126.50, 126.29, 116.72 (d, $J = 23.0$ Hz), 116.49, 53.81. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{13}\text{FNO}_3\text{S}$ $[\text{M}+\text{H}]^+$: 318.0594 found 318.0593.


5-(((4-Chlorophenyl)sulfonyl)methyl)-2-phenyloxazole (4ae). Following the general procedure (A) on a



1.0 mmol scale, giving the compound as a yellow solid (167 mg, 50%); mp 143.7~145.7 °C; IR (neat)_{vmax}: 1581, 1475, 1326, 1156, 1090, 989, 830, 634, 547 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (dd, *J* = 7.8, 1.7

Hz, 2H), 7.74 (d, *J* = 8.6 Hz, 2H), 7.48 (dd, *J* = 20.5, 8.2 Hz, 7H), 7.10 (s, 1H), 4.53 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 162.93, 141.24, 139.85, 136.24, 131.08, 130.17–129.54, 129.46–128.03, 128.63, 127.20, 126.35, 53.82; HRMS (ESI) calcd for C₁₆H₁₃ClNO₃S [M+H]⁺: 334.0297 found 334.0299.


5-(((4-Bromophenyl)sulfonyl)methyl)-2-phenyloxazole (4af). Following the general procedure (A) on a



1.0 mmol scale, giving the compound as a brown solid (242 mg, 64%); mp 148.5~150.5 °C; IR (neat)_{vmax}: 1573, 1546, 1481, 1390, 1325, 1155, 1010, 988, 826, 769, 713, 690 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.75

(dd, *J* = 7.5, 1.7 Hz, 2H), 7.59 (s, 4H), 7.37 (d, *J* = 7.0 Hz, 3H), 7.01 (s, 1H), 4.45 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 139.74, 136.77, 132.60, 130.92, 130.23–129.70, 128.84, 126.38, 53.81; HRMS (ESI) calcd for C₁₆H₁₃BrNO₃S [M+H]⁺: 377.9794 found 377.9791.


2-Phenyl-5-(((4-(trifluoromethyl)phenyl)sulfonyl)methyl)oxazole (4ag). Following the general



procedure (A) on a 1.0 mmol scale, giving the compound as a yellow solid (213 mg, 58%); mp 150.3~152.3 °C; IR (neat)_{vmax}: 1607, 1404, 1322, 1276, 1171, 1138, 1106, 989, 839, 755, 713, 689 cm⁻¹; ¹H NMR

(400 MHz, CDCl₃) δ 7.88 (d, *J* = 8.2 Hz, 2H), 7.78 – 7.66 (m, 4H), 7.42 – 7.31 (m, 3H), 7.05 (s, 1H), 4.50 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 163.05, 141.42 - 140.42 (d, *J*_{C,F} = 200.0 Hz), 139.42, 131.08, 130.08, 129.33 - 129.09 (d, *J*_{C,F} = 48.0 Hz), 128.85, 127.81, 126.57 - 126.18 (q, *J*_{C,F} = 3.0 Hz), 113.94, 68.81, 53.76, 30.98; HRMS (ESI) calcd for C₁₇H₁₃F₃NO₃S [M+H]⁺: 368.0562 found 368.0561.

5-(((Methylsulfonyl)methyl)-2-phenyloxazole (4ah). Following the general procedure (A) on a 1.0 mmol




scale, giving the compound as a brown solid (76 mg, 32%); mp 118.5~121.3°C; ¹H NMR (400 MHz, CDCl₃) δ 8.07 - 7.92 (m, 2H), 7.54 - 7.38 (m, 3H), 7.30 (s, 1H), 4.44 (s, 2H), 2.97 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 163.21, 140.19, 131.11,

130.01, 129.01, 126.78, 126.57, 52.16, 40.16; HRMS (ESI) calcd for C₁₁H₁₂O₃NS [M + H]⁺: 238.0532

found 238.0537.


2-(*p*-Tolyl)-5-(tosylmethyl)oxazole (4ba). Following the general procedure (A) on a 1.0 mmol scale,



giving the compound as a white solid (238 mg, 73%); mp 145.5~147.3 °C; IR (neat)_{vmax}: 1597, 1495, 1321, 1153, 1136, 987, 824, 757, 645, 548, 515 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.70 (dd, *J* = 26.3, 8.2 Hz, 4H),

7.34 – 7.27 (m, 2H), 7.26 – 7.19 (m, 2H), 7.01 (s, 1H), 4.49 (s, 2H), 2.41 (d, *J* = 6.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 145.34, 141.24, 139.92, 134.87, 129.84, 129.44, 128.59, 126.35, 123.93, 53.84, 21.56; HRMS (ESI) calcd for C₁₈H₁₈NO₃S [M+H]⁺: 328.1001 found 328.1000.


2-(4-Methoxyphenyl)-5-(tosylmethyl)oxazole (4ca). Following the general procedure (A) on a 1.0 mmol



scale, giving the compound as a yellow solid (216 mg, 63%); mp 131.9~133.7 °C; IR (neat)_{vmax}: 1613, 1496, 1321, 1256, 1153, 988, 839, 757, 645 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 8.9 Hz,

2H), 7.67 (d, *J* = 8.3 Hz, 2H), 7.30 (d, *J* = 8.2 Hz, 2H), 7.00 – 6.89 (m, 3H), 4.48 (s, 2H), 3.86 (s, 3H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.80, 161.63, 145.30, 139.58, 134.84, 129.82, 129.42, 128.59, 128.07, 119.42, 114.13, 55.39, 53.84, 21.61; HRMS (ESI) calcd for C₁₈H₁₈NO₄S [M+H]⁺: 344.0951 found 344.0949.


2-(3-Methoxyphenyl)-5-(tosylmethyl)oxazole (4da). Following the general procedure (A) on a 1.0 mmol



scale, giving the compound as a yellow solid (164 mg, 48%); mp 131.2~133.2 °C; IR (neat)_{vmax}: 1597, 1544, 1491, 1321, 1289, 1222, 1086, 1041, 989, 755, 686, 644, 515 cm⁻¹; ¹H NMR (400 MHz, CDCl₃)

δ 7.67 (d, *J* = 8.3 Hz, 2H), 7.45 – 7.27 (m, 5H), 7.06 – 6.95 (m, 2H), 4.50 (d, *J* = 0.7 Hz, 2H), 3.85 (s, 3H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.56, 159.78, 145.40, 140.33, 134.84, 129.84, 129.61, 128.58, 127.81, 118.78, 117.20, 111.02, 55.39, 53.80, 21.57; HRMS (ESI) calcd for C₁₈H₁₈NO₄S [M+H]⁺: 344.0951 found 344.0950.


2-(4-Fluorophenyl)-5-(tosylmethyl)oxazole (4ea). Following the general procedure (A) on a 1.0 mmol



scale, giving the compound as a yellow solid (245 mg, 74%); mp 145.2~147.2 °C; IR (neat)_{vmax}: 1610, 1495, 1322, 1237, 1154, 988,

845, 758, 646, 607, 549 cm^{-1} ; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.81 – 7.72 (m, 2H), 7.63 – 7.56 (m, 2H), 7.22 (d, $J = 7.9$ Hz, 2H), 7.03 (t, $J = 8.7$ Hz, 2H), 6.93 (s, 1H), 4.42 (s, 2H), 2.33 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.41, 164.16 (d, $J = 250.0$ Hz), 162.91, 145.35, 134.78, 129.80, 129.52, 128.47 (d, $J = 8.0$ Hz), 116.01, 115.9 (d, $J = 22.0$ Hz), 53.66, 21.54; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{15}\text{FNO}_3\text{S}$ $[\text{M}+\text{H}]^+$: 332.0751 found 332.0749.


2-(4-Chlorophenyl)-5-(tosylmethyl)oxazole (4fa). Following the general procedure (A) on a 1.0 mmol



scale, giving the compound as a light yellow solid (174 mg, 50%); mp 167.3~169.3 $^\circ\text{C}$; IR (neat) $_{\text{vmax}}$: 1597, 1481, 1321, 1151, 1135, 1090, 988, 814, 655, 551, 516 cm^{-1} ; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.80 (d, J

= 8.6 Hz, 2H), 7.68 (d, $J = 8.3$ Hz, 2H), 7.41 (d, $J = 8.6$ Hz, 2H), 7.32 (d, $J = 8.0$ Hz, 2H), 7.04 (s, 1H), 4.49 (s, 2H), 2.42 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 161.78, 145.45, 140.63, 137.07, 134.84, 129.88, 129.56, 129.10, 128.56, 127.67, 125.00, 53.73, 21.62; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{15}\text{ClNO}_3\text{S}$ $[\text{M}+\text{H}]^+$: 348.0455 found 348.0453.


2-(4-Bromophenyl)-5-(tosylmethyl)oxazole (4ga). Following the general procedure (A) on a 1.0 mmol



scale, giving the compound as a yellow solid (151 mg, 46%); mp 151.2~153.2 $^\circ\text{C}$; IR (neat) $_{\text{vmax}}$: 1602, 1478, 1402, 1321, 1153, 1010, 988, 834, 756, 645, 611, 549, 514 cm^{-1} ; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ

7.70 (dd, $J = 18.2, 8.4$ Hz, 4H), 7.56 (d, $J = 8.6$ Hz, 2H), 7.31 (d, $J = 8.0$ Hz, 2H), 7.03 (s, 1H), 4.49 (s, 2H), 2.42 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 161.86, 145.44, 140.58, 134.84, 132.02, 129.85, 128.56, 127.78, 125.60, 125.32, 113.96, 53.76, 30.98, 21.63; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{15}\text{BrNO}_3\text{S}$ $[\text{M}+\text{H}]^+$: 391.9950 found 391.9947.

2-(4-Iodophenyl)-5-(tosylmethyl)oxazole (4ha). Following the general procedure (A) on a 1.0 mmol




scale, giving the compound as a yellow solid (255 mg, 58%); mp 169.4~171.3 $^\circ\text{C}$; IR (neat) $_{\text{vmax}}$: 1600, 1320, 1275, 1153, 1074, 750, 548 cm^{-1} ; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.78 (d, $J = 8.6$ Hz, 2H), 7.67

(d, $J = 8.3$ Hz, 2H), 7.58 (d, $J = 8.6$ Hz, 2H), 7.31 (d, $J = 7.9$ Hz, 2H), 7.03 (s, 1H), 4.49 (d, $J = 0.4$ Hz, 2H), 2.42 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 145.45, 140.62, 137.98, 134.83, 129.82, 128.56, 128.35, 127.78,

126.10, 97.42, 53.76, 21.64; HRMS (ESI) calcd for C₁₇H₁₅INO₃S [M+H]⁺: 439.9811 found 439.9808.

5-(Tosylmethyl)-2-(4-(trifluoromethyl)phenyl)oxazole (4ia). Following the general procedure (A) on a



1.0 mmol scale, giving the compound as a white solid (221 mg, 58%);

mp 158.2~160.5 °C ; IR (neat)_{vmax}: 1597, 1416, 1325, 1162, 1135,

1016, 988, 851, 758 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.98 (d, *J* =


8.0 Hz, 2H), 7.69 (d, *J* = 8.0 Hz, 4H), 7.32 (d, *J* = 7.8 Hz, 2H), 7.08 (s, 1H), 4.52 (s, 2H), 2.42 (s, 3H); ¹³C

NMR (100 MHz, CDCl₃) δ 161.28 , 145.52 , 141.22 , 134.83 , 132.48 , 132.32 (d, *J*_{C,F} = 32.0 Hz), 132.16,

129.90, 128.54 , 127.57 (d, *J*_{C,F} = 194.0 Hz), 126.60, 126.30 - 125.29 (q, *J*_{C,F} = 8.0 Hz), 53.72, 21.60; HRMS

(ESI) calcd for C₁₈H₁₅F₃NO₃S [M+H]⁺: 382.0719 found 382.0716.

2-(4-Nitrophenyl)-5-(tosylmethyl)oxazole (4ja). Following the general procedure (A) on a 1.0 mmol scale,



giving the compound as a yellow solid (143 mg, 40%); mp

176.2~178.5 °C; IR (neat)_{vmax}: 1523, 1339, 1275, 1241, 1069, 859,

645 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.30 (d, *J* = 9.0 Hz, 2H), 8.06


(d, *J* = 9.1 Hz, 2H), 7.70 (d, *J* = 8.3 Hz, 2H), 7.34 (dd, *J* = 8.5, 0.6 Hz, 2H), 7.13 (s, 1H), 4.53 (d, *J* = 0.7

Hz, 2H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 145.64, 141.95, 134.83, 132.05, 130.44, 129.98,

128.56, 127.14, 124.15, 53.70, 21.68; HRMS (ESI) calcd for C₁₇H₁₅N₂O₅S [M+H]⁺: 359.0696 found

359.0694.

2-Nonyl-5-(tosylmethyl)oxazole (4ka). Following the general procedure (A) on a 1.0 mmol scale, giving



the compound as a yellow viscous oil (182 mg, 50%); IR

(neat)_{vmax}: 1725, 1598, 1561, 1466, 1325, 1154, 1087, 990,

817, 756, 643, 550, 514 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ


7.64 (d, *J* = 8.1 Hz, 2H), 7.32 (d, *J* = 8.0 Hz, 2H), 6.82 (s, 1H), 4.40 (s, 2H), 2.68 (t, *J* = 7.6 Hz, 2H), 2.45 (s,

3H), 1.63 (s, 2H), 1.35 – 1.20 (m, 16H), 0.88 (t, *J* = 6.8 Hz, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 145.43,

140.02, 134.85, 129.95, 128.60, 127.89, 53.52, 31.70, 29.06, 27.88, 26.67, 22.48, 21.50, 13.91; HRMS (ESI)


calcd for C₂₆H₃₄NO₃S [M+H]⁺: 364.1941 found 364.1950.

2-(5-Nitrofuran-2-yl)-5-(tosylmethyl)oxazole (4la). Following the general procedure (A) on a 1.0 mmol




scale, giving the compound as a brown solid (164 mg, 47%); mp 151.0~153.3 °C; IR (neat)_{vmax}: 1686, 1519, 1353, 1259, 1154, 967, 812, 647 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, *J* = 8.3 Hz, 2H), 7.39 (dd, *J* = 16.4, 5.9 Hz, 4H), 7.19 – 7.09 (m, 2H), 4.52 (s, 2H), 2.46 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.65, 145.85, 143.09, 142.30, 134.63, 130.39, 130.08, 128.50, 116.78, 113.44, 112.65, 112.32, 53.48, 21.69; HRMS (ESI) calcd for C₁₅H₁₂N₂NaO₆S [M+Na]⁺: 371.0308 found 371.0306.

2-(4-Chlorophenyl)-5-(phenyl(tosyl)methyl)oxazole (4ma). Following the general procedure (A) on a




1.0 mmol scale, giving the compound as a yellow solid (288 mg, 68%); mp 143.9~145.5 °C; IR (neat)_{vmax}: 1710, 1542, 1482, 1455, 1405, 1321, 1148, 1093, 1013, 838, 814, 703, 670, 564 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, *J* = 8.8 Hz, 2H), 7.54 – 7.46 (m, 4H), 7.44 – 7.36 (m, 5H), 7.30 – 7.25 (m, 1H), 7.24 – 7.20 (m, 2H), 5.49 (s, 1H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.49, 145.25, 143.97, 136.87, 134.06, 130.28, 129.83–129.40, 129.39–128.68, 128.60, 127.79–127.24, 125.31, 69.05, 21.65; HRMS (ESI) calcd for C₂₃H₁₉ClNO₃S [M+H]⁺: 424.0768 found 424.0766.

(E)-4,4-Dimethyl-2-phenyl-5-(tosylmethylene)-4,5-dihydrooxazole (4na). Following the general



procedure (A) on a 1.0 mmol scale, giving the compound as a light brown solid (181 mg, 53%); mp 99.7~101.7 °C; IR (neat)_{vmax}: 1674, 1632, 1597, 1321, 1290, 1174, 1150, 1048, 1022, 936, 847, 813, 692, 662, 582 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.93 – 7.91 (m, 1H), 7.90 (d, *J* = 1.4 Hz, 1H), 7.84 (s, 1H), 7.82 (s, 1H), 7.52 (d, *J* = 7.5 Hz, 1H), 7.47 – 7.41 (m, 2H), 7.35 (dd, *J* = 8.6, 0.6 Hz, 2H), 6.21 (s, 1H), 2.44 (s, 3H), 1.86 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 173.42, 157.55, 144.08, 139.68, 132.27, 129.92, 128.66, 128.12, 127.06, 106.11, 73.19, 26.57, 21.58; HRMS (ESI) calcd for C₁₉H₂₀NO₃S [M+H]⁺: 342.1158 found 342.1156.

(E)-2-Phenyl-4-(tosylmethylene)-3-oxa-1-azaspiro[4.5]dec-1-ene (4oa). Following the general




procedure (A) on a 1.0 mmol scale, giving the compound as a yellow solid (191 mg, 50%); mp 30.2~33.7 °C; IR (neat)_{vmax}: 1675, 1625, 1450, 1322, 1278, 1154, 1046, 1022, 692, 661, 588 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.97 – 7.90 (m, 2H), 7.83 (d,

$J = 8.3$ Hz, 2H), 7.50 (d, $J = 7.4$ Hz, 1H), 7.43 (t, $J = 7.5$ Hz, 2H), 7.34 (d, $J = 8.1$ Hz, 2H), 6.16 (s, 1H), 2.85 (td, $J = 13.0, 4.1$ Hz, 2H), 2.44 (s, 3H), 2.00 – 1.79 (m, 3H), 1.74 (d, $J = 13.0$ Hz, 2H), 1.68 – 1.51 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.99, 156.56, 143.92, 139.87, 131.97, 129.81, 128.53, 128.11, 126.99, 125.86, 105.87, 34.90, 24.89, 22.27, 21.55; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{24}\text{NO}_3\text{S}$ $[\text{M}+\text{H}]^+$: 382.1471 found 382.1468.


General procedure (B) for preparation of sulfenylated oxazolines

Procedure for the synthesis of 2-Phenyl-5-((*p*-tolylthio)methyl)-4,5-dihydrooxazole (6aa).




To a stirred solution of *N*-allyl benzamide **5a** (160 mg, 1.0 equiv) in toluene (2.0 mL) was added tosylhydrazide **2a** (280 mg, 1.5 equiv), and iodine (254 mg, 1.0 equiv). The reaction mixture was heated to reflux. The completion of reaction was monitored by TLC chromatography. After completion, the reaction mixture was cooled to room temperature and diluted with 10 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was then given brine wash (2X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to get the crude compound. The obtained crude was then purified using column chromatography using neutral alumina by eluting from hexane to 20% ethyl acetate/hexane to afford pure 2-Phenyl-5-((*p*-tolylthio)methyl)-4,5-dihydrooxazole (**6aa**) as a yellow liquid (184 mg, 65%); ^1H NMR (400 MHz, CDCl_3) δ 7.88 – 7.81 (m, 2H), 7.50 – 7.30 (m, 5H), 7.13 – 7.06 (m, 2H), 4.86 – 4.75 (m, 1H), 4.13 (dd, $J = 15.0, 9.5$ Hz, 1H), 3.87 (dd, $J = 15.0, 6.8$ Hz, 1H), 3.27 (dd, $J = 13.7, 5.5$ Hz, 1H), 3.01 (dd, $J = 13.7, 7.2$ Hz, 1H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.66, 137.05, 131.46, 131.16, 129.81, 128.51–127.99, 127.52, 78.25, 60.71, 59.54, 39.09, 29.65, 20.99, 7.61; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{18}\text{NOS}$ $[\text{M}+\text{H}]^+$: 284.1104 found 284.1112.

2-Phenyl-5-((phenylthio)methyl)-4,5-dihydrooxazole (6ba). Following the general procedure (B) on a




1.0 mmol scale, giving the compound as a yellow viscous oil (167 mg, 62 %); ^1H NMR (400 MHz, CDCl_3) δ 7.86 (dd, $J = 8.3, 1.2$ Hz, 2H), 7.42 (ddt, $J = 13.5, 8.5, 7.3$ Hz, 5H), 7.32 – 7.19 (m, 3H), 4.90 – 4.79 (m, 1H), 4.16 (dd, $J = 15.0, 9.5$ Hz, 1H), 3.89 (dd, $J = 15.0, 6.7$ Hz, 1H), 3.33 (dd, $J = 13.7, 5.5$ Hz, 1H), 3.07 (dd, $J = 13.7, 7.1$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 134.92, 131.35, 130.33, 129.08, 128.20, 126.79, 78.15, 59.61, 38.47, 29.69; HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{16}\text{NOS}$ $[\text{M}+\text{H}]^+$: 270.0947 found 270.0952.

5-(((4-Bromophenyl)thio)methyl)-2-phenyl-4,5-dihydrooxazole (6af). Following the general procedure




(B) on a 1.0 mmol scale, giving the compound as a yellow viscous oil (174 mg, 50 %); ^1H NMR (400 MHz, CDCl_3) δ 7.80 (dd, $J = 8.4, 1.3$ Hz, 2H), 7.50 – 7.35 (m, 5H), 7.31 – 7.25 (m, 2H), 4.86 (dd, $J = 9.5, 5.7$ Hz, 1H), 4.16 (dd, $J = 15.0, 9.5$ Hz, 1H), 3.88 (dd, $J = 15.0, 6.7$ Hz, 1H), 3.27 (dd, $J = 13.9, 5.7$ Hz, 1H), 3.10 (dd, $J = 13.9, 6.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 131.98, 131.41, 128.29, 128.07, 120.76, 78.15, 59.54, 38.63; HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{15}\text{BrNOS}$ $[\text{M}+\text{H}]^+$: 348.0052 found 348.0065.

5-((Methylthio)methyl)-2-phenyl-4,5-dihydrooxazole (6ah). Following the general procedure (B) on a 1.0



mmol scale, giving the compound as a yellow viscous oil (83 mg, 40%); ^1H NMR (400 MHz, CDCl_3) δ 7.97 - 7.91 (m, 2H), 7.51 - 7.45 (m, 1H), 7.45 - 7.37 (m, 2H), 4.97 - 4.80 (m, 1H), 4.19 (dd, $J = 14.9, 9.4$ Hz, 1H), 3.85 (q, $J = 7.3$ Hz, 1H), 2.86 (dd, $J = 14.2, 6.0$ Hz, 1H), 2.77 - 2.63 (m, 1H), 2.22 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.84, 131.45, 128.44, 128.22, 127.73, 79.24, 59.87, 38.66, 16.50; HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{14}\text{ONS}$ $[\text{M} + \text{H}]^+$: 208.0791 found 208.0788.


2-(*p*-Tolyl)-5-((*p*-tolylthio)methyl)-4,5-dihydrooxazole (6ba). Following the general procedure (B) on a



1.0 mmol scale, giving the compound as a yellow viscous oil (128 mg, 43 %); ^1H NMR (400 MHz, CDCl_3) δ 7.74 (d, $J = 8.2$ Hz, 2H), 7.34 (d, $J = 8.1$ Hz, 2H), 7.18 (d, $J = 8.0$ Hz, 2H), 7.10 (d, $J = 8.0$ Hz, 2H), 4.84 – 4.73 (m, 1H), 4.12 (dd, $J = 14.9, 9.5$ Hz, 1H), 3.85 (dd, $J = 14.9, 6.8$ Hz, 1H), 3.27 (dd, $J = 13.7, 5.5$ Hz, 1H), 3.00 (dd, $J = 13.7, 7.3$ Hz, 1H), 2.38 (d, $J = 4.9$ Hz, 3H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ

163.81, 141.67, 137.04, 131.14, 129.82, 129.00, 128.09, 124.70, 78.17, 60.66, 59.47, 39.10, 21.52, 21.00, 7.69; HRMS (ESI) calcd for C₁₈H₂₀NOS [M+H]⁺: 298.1260 found 298.1268.

5-((Methylthio)methyl)-2-(p-tolyl)-4,5-dihydrooxazole (6bh). Following the general procedure (B) on a



1.0 mmol scale, giving the compound as a yellow viscous oil (100 mg, 45%); ¹H

NMR (400 MHz, CDCl₃) δ 7.82 (d, *J* = 8.2 Hz, 2H), 7.21 (d, *J* = 8.2 Hz, 2H),


4.93 - 4.83 (m, 1H), 4.17 (dd, *J* = 14.7, 9.6 Hz, 1H), 3.84 (q, *J* = 7.3 Hz, 1H),

2.86 (dd, *J* = 14.2, 6.0 Hz, 1H), 2.72 (q, *J* = 6.9 Hz, 1H), 2.39 (s, 3H), 2.21 (s, 3H); ¹³C NMR (100 MHz,

CDCl₃) δ 163.94, 141.83, 129.15, 128.18, 124.94, 79.14, 59.82, 38.67, 21.63, 16.50; HRMS (ESI) calcd for

C₁₂H₁₆ONS [M + H]⁺: 222.0947 found 222.0943.

2-(4-Fluorophenyl)-5-(p-tolylthio)methyl)-4,5-dihydrooxazole (6ca). Following the general procedure



(B) on a 1.0 mmol scale, giving the compound as a yellow viscous oil

(120 mg, 40 %); ¹H NMR (400 MHz, CDCl₃) δ 7.88 – 7.79 (m, 2H),

7.37 – 7.30 (m, 2H), 7.15 – 7.01 (m, 4H), 4.87 – 4.77 (m, 1H), 4.12 (dd, *J*


= 15.0, 9.5 Hz, 1H), 3.86 (dd, *J* = 14.9, 6.8 Hz, 1H), 3.26 (dd, *J* = 13.8, 5.6 Hz, 1H), 3.03 (dd, *J* = 13.8, 7.0

Hz, 1H), 2.32 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.87, 164.63 (d, *J* = 249.0 Hz), 162.81, 137.14,

131.13, 130.36 (d, *J* = 8.8 Hz), 129.84, 123.76, 115.46 - 115.24 (d, *J* = 22.0 Hz), 78.50, 59.55, 39.12, 29.68,

21.02; HRMS (ESI) calcd for C₁₇H₁₇FNOS [M+H]⁺: 302.1009 found 302.1018.

Procedure for the synthesis of (E)-N-(2-Iodo-3-tosylallyl)benzamide (3aa). To a stirred solution of



N-propynyl benzamide **1a** (160 mg, 1.0 equiv) in acetonitrile (2.0 mL) was added

tosyllhydrazide **2a** (372 mg, 2.0 equiv), TBHP solution 70% in H₂O (258 μL, 2.0

equiv) and iodine (128 mg, 50 mol %). The reaction mixture was heated to 90 °C.

The completion of reaction was monitored by TLC chromatography. After the completion, the reaction was

diluted with 10 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the

combined ethyl acetate layer was then given brine wash (2X10 mL). The final ethyl acetate layer was dried


over sodium sulfate and concentrated under reduced pressure to get the crude compound. The obtained crude

was then purified using column chromatography by eluting from hexane to 15% ethyl acetate/hexane to

afford pure (E)-N-(2-Iodo-3-tosylallyl)benzamide ¹H NMR (400 MHz, CDCl₃) δ 7.91 – 7.80 (m, 4H), 7.57 –

7.43 (m, 3H), 7.41 – 7.36 (m, 2H), 7.17 (t, $J = 1.1$ Hz, 1H), 6.81 (s, 1H), 4.91 (dd, $J = 6.3, 1.1$ Hz, 2H), 2.45 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.09, 145.42, 140.69, 136.89, 133.64, 131.93, 130.32, 128.68, 127.68, 127.14, 119.92, 45.47, 21.71; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{17}\text{NO}_3\text{NIS}$ $[\text{M}+\text{H}]^+$: 441.9968 found 441.9982.

Procedure for the synthesis of (*E*)-*N*-(2-Iodo-3-tosylallyl)-4-nitrobenzamide (3ja**).** To a stirred solution




of 4-nitro-*N*-(prop-2-yn-1-yl)benzamide **3a** (204 mg, 1.0 equiv) in acetonitrile (2.0 mL) was added tosylhydrazide **2a** (372 mg, 2.0 equiv), TBHP solution 70% in H_2O (258 μL , 2.0 equiv) and iodine (128 mg, 50 mol %). The reaction

mixture was heated to 90 °C. The completion of reaction was monitored by TLC chromatography. After the completion, the reaction was diluted with 10 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was then given brine wash (2X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to get the crude compound. The obtained crude was then purified using column chromatography by eluting from hexane to 15% ethyl acetate/hexane to afford pure (*E*)-*N*-(2-Iodo-3-tosylallyl)-4-nitrobenzamide (**3ja**). ^1H NMR (400 MHz, CDCl_3) δ 8.31 (d, $J = 8.7$ Hz, 2H), 8.01 (d, $J = 8.8$ Hz, 2H), 7.86 (d, $J = 8.3$ Hz, 2H), 7.41 (d, $J = 8.0$ Hz, 2H), 7.18 (s, 1H), 7.06 (s, 1H), 4.95 (d, $J = 6.0$ Hz, 2H), 2.47 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.18, 145.69, 141.13, 139.17, 136.57, 130.40, 128.42, 127.68, 123.92, 117.84, 45.99, 21.75; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_5\text{IS}$ $[\text{M}+\text{H}]^+$: 486.9819 found 486.9834.

4) CCDC 145160-145167, 1473425

Summary of Data CCDC 1465160

Compound Name: 2-Phenyl-5-(tosylmethyl)oxazole




Formula: $\text{C}_{17}\text{H}_{15}\text{N}_1\text{O}_3\text{S}_1$

Unit Cell Parameters: a 6.0578(6) b 11.1512(14) c 11.9001(15) P-1

Summary of Data CCDC 1465161

Compound Name: 2-Phenyl-5-((phenylsulfonyl)methyl)oxazole




Formula: C₁₆ H₁₃ N₁ O₃ S₁

Unit Cell Parameters: a 5.8951(3) b 10.7554(8) c 11.3589(8) P-1

Summary of Data CCDC 1465162

Compound Name: (*E*)-2-Phenyl-4-(tosylmethylene)-3-oxa-1-azaspiro[4.5]dec-1-ene




Formula: C₂₂ H₂₃ N₁ O₃ S₁

Unit Cell Parameters: a 9.8639(12) b 21.953(3) c 10.1344(11) Cc

Summary of Data CCDC 1465163

Compound Name: 5-(((4-Fluorophenyl)sulfonyl)methyl)-2-phenyloxazole




Formula: C₁₆ H₁₂ F₁ N₁ O₃ S₁

Unit Cell Parameters: a 6.2389(3) b 9.1551(6) c 13.2937(8) P-1

Summary of Data CCDC 1465164

Compound Name: 5-(((4-Bromophenyl)sulfonyl)methyl)-2-phenyloxazole




Formula: C₁₆ H₁₂ Br₁ N₁ O₃ S₁

Unit Cell Parameters: a 6.0573(8) b 9.8062(15) c 13.5008(17) P-1

Summary of Data CCDC 1465165

Compound Name: 2-Phenyl-5-(((4-(trifluoromethyl)phenyl)sulfonyl)methyl)oxazole




Formula: C₁₇ H₁₂ F₃ N₁ O₃ S₁

Unit Cell Parameters: a 6.1164(12) b 9.942(3) c 13.652(3) P-1

Summary of Data CCDC 1465166

Compound Name: 5-(((4-Methoxyphenyl)sulfonyl)methyl)-2-phenyloxazole




Formula: C₁₇ H₁₅ N₁ O₄ S₁

Unit Cell Parameters: a 6.1602(11) b 10.664(2) c 13.258(3) P-1

Summary of Data CCDC 1465167

Compound Name: 2-(4-Chlorophenyl)-5-(phenyl(tosyl)methyl)oxazole




Formula: C₂₃ H₁₈ Cl₁ N₁ O₃ S₁

Unit Cell Parameters: a 13.752(3) b 8.4132(13) c 19.307(3) P21/c

Summary of Data CCDC 1473425



Compound Name: (*E*)-*N*-(2-Iodo-3-tosylallyl)-4-nitrobenzamide



Formula: C₁₇ H₁₅ I₁ N₂ O₅ S₁

Unit Cell Parameters: a 10.3360(7) b 13.7149(9) c 14.1776(8) P-1

5) X-ray Crystallography Data



Datablock: I

Bond precision: C-C = 0.0044 Å

Wavelength=0.71073

Cell: a=6.0578 (6) b=11.1512 (14) c=11.9001 (15)
alpha=71.535 (12) beta=86.207 (9) gamma=89.004 (9)
Temperature: 297 K



	Calculated	Reported
Volume	760.81 (16)	760.81 (15)
Space group	P -1	P -1
Hall group	-P 1	?
Moiety formula	C17 H15 N O3 S	C17 H15 N O3 S
Sum formula	C17 H15 N O3 S	C17 H15 N O3 S
Mr	313.36	313.36
Dx, g cm ⁻³	1.368	1.368
Z	2	2
Mu (mm ⁻¹)	0.224	0.224
F000	328.0	328.0
F000'	328.39	
h, k, lmax	8, 15, 16	8, 13, 16
Nref	4138	3490
Tmin, Tmax	0.953, 0.982	0.986, 1.000
Tmin'	0.904	

Correction method= # Reported T Limits: Tmin=0.986 Tmax=1.000
AbsCorr = MULTI-SCAN

Data completeness= 0.843 Theta(max) = 29.200

R(reflections)= 0.0604 (1988) wR2(reflections)= 0.1440 (3490)

S = 0.991 Npar= 199



Datablock: I

Bond precision: C-C = 0.0030 Å

Wavelength=0.71073

Cell: a=5.8951(3)

b=10.7554(8)

c=11.3589(8)

alpha=75.588(3)

beta=86.378(2)

gamma=81.134(2)

Temperature: 150 K

	Calculated	Reported
Volume	688.97(8)	688.97(8)
Space group	P -1	P -1
Hall group	-P 1	?
Moiety formula	C16 H13 N O3 S	C16 H13 N O3 S
Sum formula	C16 H13 N O3 S	C16 H13 N O3 S
Mr	299.33	299.33
Dx, g cm ⁻³	1.443	1.443
Z	2	2
Mu (mm ⁻¹)	0.244	0.244
F000	312.0	312.0
F000'	312.39	
h,k,lmax	7,13,14	7,13,14
Nref	2821	2809
Tmin,Tmax	0.940,0.964	0.902,0.964
Tmin'	0.900	

Correction method= # Reported T Limits: Tmin=0.902 Tmax=0.964

AbsCorr = MULTI-SCAN

Data completeness= 0.996



Theta(max)= 26.390

R(reflections)= 0.0365(2256)

wR2(reflections)= 0.1110(2809)

S = 1.057

Npar= 190



Datablock: rp2007

Bond precision: C-C = 0.0117 Å

Wavelength=0.71073

Cell: a=6.1602 (11) b=10.664 (2) c=13.258 (3)
 alpha=103.005 (18) beta=102.402 (16) gamma=106.112 (16)
 Temperature: 297 K

	Calculated	Reported
Volume	778.7 (3)	778.7 (3)
Space group	P -1	P -1
Hall group	-P 1	-P 1
Moiety formula	C17 H15 N O4 S	C17 H15 N O4 S
Sum formula	C17 H15 N O4 S	C17 H15 N O4 S
Mr	329.36	329.36
Dx, g cm ⁻³	1.405	1.405
Z	2	2
Mu (mm ⁻¹)	0.228	0.228
F000	344.0	344.0
F000'	344.41	
h,k,lmax	8,14,18	8,14,16
Nref	4223	3550
Tmin,Tmax	0.914,0.973	0.563,1.000
Tmin'	0.862	

Correction method= # Reported T Limits: Tmin=0.563 Tmax=1.000
 AbsCorr = MULTI-SCAN

Data completeness= 0.841



Theta(max)= 29.180

R(reflections)= 0.1740 (2033)

wR2(reflections)= 0.4576 (3550)

S = 1.377

Npar= 208



Datablock: I

Bond precision: C-C = 0.0029 Å

Wavelength=0.71073

Cell: a=6.2389 (3)

b=9.1551 (6)

c=13.2937 (8)

alpha=72.550 (2)

beta=81.797 (2)

gamma=75.434 (2)

Temperature: 150 K

	Calculated	Reported
Volume	699.22 (7)	699.22 (7)
Space group	P -1	P -1
Hall group	-P 1	?
Moiety formula	C16 H12 F N O3 S	C16 H12 F N O3 S
Sum formula	C16 H12 F N O3 S	C16 H12 F N O3 S
Mr	317.33	317.33
Dx, g cm ⁻³	1.507	1.507
Z	2	2
Mu (mm ⁻¹)	0.255	0.255
F000	328.0	328.0
F000'	328.42	
h, k, lmax	7, 11, 16	7, 11, 16
Nref	2885	2880
Tmin, Tmax	0.929, 0.967	0.900, 0.968
Tmin'	0.898	

Correction method= # Reported T Limits: Tmin=0.900 Tmax=0.968

AbsCorr = MULTI-SCAN

Data completeness= 0.998



Theta(max)= 26.440

R(reflections)= 0.0346 (2446)

wR2(reflections)= 0.0933 (2880)

S = 1.026

Npar= 199



Datablock: I

Bond precision: C-C = 0.0083 A

Wavelength=0.71073

Cell: a=6.0573 (8) b=9.8062 (15) c=13.5008 (17)
 alpha=70.435 (13) beta=82.679 (10) gamma=82.699 (11)
 Temperature: 297 K

	Calculated	Reported
Volume	746.41 (19)	746.41 (18)
Space group	P -1	P -1
Hall group	-P 1	?
Moiety formula	C16 H12 Br N O3 S	C16 H12 Br N O3 S
Sum formula	C16 H12 Br N O3 S	C16 H12 Br N O3 S
Mr	378.23	378.24
Dx, g cm-3	1.683	1.683
Z	2	2
Mu (mm-1)	2.905	2.905
F000	380.0	380.0
F000'	379.83	
h, k, lmax	8, 13, 18	8, 12, 18
Nref	4094	3452
Tmin, Tmax	0.599, 0.685	0.969, 1.000
Tmin'	0.150	

Correction method= # Reported T Limits: Tmin=0.969 Tmax=1.000

AbsCorr = MULTI-SCAN

Data completeness= 0.843



Theta(max)= 29.310

R(reflections)= 0.0719(2269)

wR2(reflections)= 0.1985(3452)

S = 1.054

Npar= 199



Datablock: I

Bond precision: C-C = 0.0061 Å Wavelength=0.71073

Cell: a=6.1164 (12) b=9.942 (3) c=13.652 (3)
alpha=72.21 (2) beta=84.375 (18) gamma=87.05 (2)

Temperature: 297 K



	Calculated	Reported
Volume	786.5 (3)	786.5 (3)
Space group	P -1	P -1
Hall group	-P 1	?
Moiety formula	C17 H12 F3 N O3 S	C17 H12 F3 N O3 S
Sum formula	C17 H12 F3 N O3 S	C17 H12 F3 N O3 S
Mr	367.34	367.34
Dx, g cm ⁻³	1.551	1.551
Z	2	2
Mu (mm ⁻¹)	0.256	0.256
F000	376.0	376.0
F000'	376.49	
h,k,lmax	8,13,18	8,13,18
Nref	4262	3584
Tmin,Tmax	0.935,0.950	0.883,1.000
Tmin'	0.840	

Correction method= # Reported T Limits: Tmin=0.883 Tmax=1.000
AbsCorr = MULTI-SCAN

Data completeness= 0.841 Theta(max)= 29.170

R(reflections)= 0.0895 (2191) wR2(reflections)= 0.2694 (3584)

S = 1.070 Npar= 226



Datablock: I

Bond precision: C-C = 0.0036 Å

Wavelength=0.71073

Cell: a=9.8639 (12) b=21.953 (3) c=10.1344 (11)
alpha=90 beta=115.004 (4) gamma=90

Temperature: 302 K

	Calculated	Reported
Volume	1988.9 (4)	1988.8 (4)
Space group	C c	C c
Hall group	C -2yc	?
Moiety formula	C22 H23 N O3 S	C22 H23 N O3 S
Sum formula	C22 H23 N O3 S	C22 H23 N O3 S
Mr	381.47	381.47
Dx, g cm ⁻³	1.274	1.274
Z	4	4
Mu (mm ⁻¹)	0.184	0.184
F000	808.0	808.0
F000'	808.84	
h, k, lmax	12, 27, 12	12, 27, 12
Nref	4069 [2041]	3891
Tmin, Tmax	0.926, 0.948	0.912, 0.948
Tmin'	0.910	

Correction method= # Reported T Limits: Tmin=0.912 Tmax=0.948
AbsCorr = MULTI-SCAN

Data completeness= 1.91/0.96



Theta(max)= 26.370

R(reflections)= 0.0352 (3417)

wR2(reflections)= 0.0870 (3891)

S = 1.034

Npar= 244



Datablock: rp2109

Bond precision: C-C = 0.0104 Å Wavelength=0.71073

Cell: a=13.752 (3) b=8.4132 (13) c=19.307 (3)
 alpha=90 beta=110.58 (2) gamma=90

Temperature: 297 K



	Calculated	Reported
Volume	2091.2 (7)	2091.2 (7)
Space group	P 21/c	P 21/c
Hall group	-P 2ybc	-P 2ybc
Moiety formula	C ₂₃ H ₁₈ Cl N O ₃ S	C ₂₃ H ₁₈ Cl N O ₃ S
Sum formula	C ₂₃ H ₁₈ Cl N O ₃ S	C ₂₃ H ₁₈ Cl N O ₃ S
Mr	423.89	423.89
Dx, g cm ⁻³	1.346	1.346
Z	4	4
Mu (mm ⁻¹)	0.307	0.307
F ₀₀₀	880.0	880.0
F ₀₀₀ '	881.44	
h, k, lmax	18, 11, 26	18, 11, 25
Nref	5665	4749
Tmin, Tmax	0.866, 0.926	0.858, 1.000
Tmin'	0.850	

Correction method= # Reported T Limits: Tmin=0.858 Tmax=1.000
 AbsCorr = MULTI-SCAN

Data completeness= 0.838 Theta(max)= 29.193

R(reflections)= 0.1164 (2502) wR2(reflections)= 0.3860 (4749)

S = 1.131 Npar= 263



Datablock: rp2148

Bond precision: C-C = 0.0114 Å

Wavelength=0.71073

Cell: a=10.3360(7)

b=13.7149(9)

c=14.1776(8)

alpha=85.839(5)

beta=74.352(6)

gamma=76.639(6)

Temperature: 297 K

	Calculated	Reported
Volume	1882.8(2)	1882.8(2)
Space group	P -1	P -1
Hall group	-P 1	-P 1
Moiety formula	C17 H15 I N2 O5 S	C17 H15 I N2 O5 S
Sum formula	C17 H15 I N2 O5 S	C17 H15 I N2 O5 S
Mr	486.27	486.27
Dx, g cm ⁻³	1.715	1.715
Z	4	4
Mu (mm ⁻¹)	1.842	1.842
F000	960.0	960.0
F000'	959.01	
h, k, lmax	14, 18, 19	13, 18, 19
Nref	10410	8636
Tmin, Tmax	0.725, 0.802	0.831, 1.000
Tmin'	0.340	

Correction method= # Reported T Limits: Tmin=0.831 Tmax=1.000

AbsCorr = MULTI-SCAN

Data completeness= 0.830

Theta(max)= 29.406

R(reflections)= 0.0698(5253)

wR2(reflections)= 0.1979(8636)




S = 1.044



Npar= 471

6) References




1. Á. Sinai, D. Vangel, T. Gáti, P. Bombicz, and Z. Novák, *Org. Lett.*, 2015, **17**, 4136.
2. B. Rajagopal, Y.Y. Chen, C. C. Chen, X. Y. Liu, H. R. Wang, and P. C. Lin, *J. Org. Chem.*, 2014, **79**, 1254.
3. K. Liu, H. Shi, H. Xiao, A. G. L. Chong, X. Bi, Y. T. Chang, K. S. W. Tan, R. Y. Yada, S. Q. Yao, *Angew. Chem. Int. Ed.*, 2009, **48**, 8293.
4. S. Yasuhara, M. Sasa, T. Kusakabe, H. Takayama, M. Kimura, T. Mochida, and K. Kato, *Angew. Chem. Int. Ed.*, 2011, **50**, 3912.
5. A. S. K. Hashmi, M. C. B. Jaimes, A. M. Schuster, and F. Rominger, *J. Org. Chem.*, 2012, **77**, 6394.
6. G. C. Feast, O. E. Hutt, X. Mulet, C. E. Conn, C. J. Drummond, and G. P. Savage, *Chem. Eur. J.*, 2014, **20**, 2783.
7. A. S. K. Hashmi, J. P. Weyrauch, W. Frey, and J. W. Bats, *Org. Lett.*, 2004, **6**, 4391.
8. R. M. Myers, S. P. Langston, S. P. Conway, and C. Abell, *Org. Lett.*, 2000, **2**, 1349.
9. A. S. K. Hashmi, A. M. Schuster, M. Schmuck, and F. Rominger, *Eur. J. Org. Chem.*, 2011, **2011**, 4595–4602.
10. S. Das, Y. Li, L. Q. Lu, K. Junge, and M. Beller, *Chem. Eur. J.*, 2016, **22**, 7050.
11. W. R. Bowman, A. J. Fletcher, J. M. Pedersen, P. J. Lovell, M. R. J. Elsegood, E. H. Lopez, V. McKee and G. B. S. Potts, *Tetrahedron Lett.*, 2007, **63**, 191.
12. L. Xu, H. Li, Z. Liao, K. Lou, H. Xie, H. Li, and W. Wang, *Org. Lett.* 2015, **17**, 3434.

Solvent: CDCl₃
Frequency: 400.40 MHz









Vera-RP1-165s
Pulse Sequence: DEPT






Solvent: CDCl₃
Frequency: 400.40 MHz









Vera-02

Pulse Sequence: DEPT






Solvent: CDCl₃
Frequency: 400.40 MHz









Vera-03

Pulse Sequence: DEPT






Solvent: CDCl₃
Frequency: 400.40 MHz









Vera-01
Pulse Sequence: DEPT






Solvent: CDCl₃
Frequency: 400.40 MHz










Vera-RP2-72s

Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz







Vera-RP2-82s
Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz





4.25
4.24
4.23


2.30
2.29
2.28










Vera-RP2-99s
Pulse Sequence: DEPT











Vera-RP2-1065
Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.28 MHz








Vera-RP2-76S

Pulse Sequence: DEPT














Vera-05

Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz









Vera-RP2-156s
Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.28 MHz










Vera-RP2-103s

Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.28 MHz








Vera-RP3-03
Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz








Vera-04



Pulse Sequence: DEPT












Vera-RP2-151s
Pulse Sequence: DEPT






Solvent: CDCl₃
Frequency: 400.40 MHz









Vera-RP1-166m
Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz








Vera-RP2-147
Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz







vera-RP1-166

Pulse Sequence: DEPT








137.83
134.23
130.82
129.72
129.25
128.76
128.56
126.36

77.32
77.00
76.68



53.74





S85



vera-RP1-178

Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz








vera-RP2-07

Pulse Sequence: DEPT










vera-RP2-09

Pulse Sequence: DEPT







Solvent: CDCl₃
Frequency: 400.40 MHz



7.86
7.84
7.84
7.75
7.73
7.51
7.49
7.46
7.44
7.10



4.53









vera-RP2-18

Pulse Sequence: DEPT



Solvent: CDCl₃
Frequency: 400.40 MHz









139.74
136.77
132.65
130.92
130.09
129.94
129.80
128.84
126.45
126.31

77.32
77.00
76.68


53.81



vera-RP1-174
Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.28 MHz





7.89
7.87
7.74
7.72
7.71
7.69
7.39
7.38
7.36
7.35

4.50




7.89
7.87
7.74
7.72
7.71
7.69
7.39
7.38
7.36
7.35
7.34
7.05








S100

Vera-RP2-11
Pulse Sequence: DEPT













Solvent: CDCl3
Frequency: 400.28 MHz








145.34
141.24
139.92
134.87
129.84
129.44
128.59
126.35
123.93
77.52
77.00
76.68
53.84
21.61
21.52





S106



vera-RP2-49

Pulse Sequence: DEPT






Solvent: CDCl₃
Frequency: 400.40 MHz








S109

Vera-RP2-108
Pulse Sequence: DEPT








Vera-RP2-98
Pulse Sequence: DEPT



Solvent: CDCl3
Frequency: 400.40 MHz










S115



vera-RP2-72

Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.28 MHz









S118

vera-RP2-082
Pulse Sequence: DEPT






Solvent: CDCl₃
Frequency: 400.40 MHz






S121

Vera-RP2-99
Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz





7.79
7.77
7.68
7.66
7.59
7.57
7.32
7.30
7.03

4.49
4.49



2.42









S124

Vera-RP2-106
Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz









Vera-RP2-76

Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz











S130

Vera-RP2-148
Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz







S133



Vera-RP2-156
Pulse Sequence: DEPT



Solvent: CDCl₃
Frequency: 400.40 MHz





S135




S136

vera-RP2-103

Pulse Sequence: DEPT





Solvent: CDCl₃
Frequency: 400.40 MHz





7.88
7.86
7.53
7.51
7.50
7.49
7.48
7.47
7.43
7.41
7.39
7.37
7.36
7.30
7.26
7.23
7.21
7.20

5.49



2.40







S139

Vera-RP2-109
Pulse Sequence: DEPT




Solvent: CDCl₃
Frequency: 400.40 MHz





-2.44

-1.86





S141




S142

Vera-RP2-159
Pulse Sequence: DEPT








Solvent: CDCl₃
Frequency: 400.40 MHz



7.94
7.92
7.92
7.84
7.82
7.51
7.49
7.44
7.43
7.41
7.35
7.33
-6.16




2.89
2.87
2.85
2.84
2.82
2.81
-2.44
1.95
1.92
1.91
1.75
1.72
1.66
1.63
1.62









S145

Vera-RP2-151
Pulse Sequence: DEPT



Solvent: CDCl₃
Frequency: 400.28 MHz












S148


Vera-RP3-27

Pulse Sequence: DEPT



Solvent: CDCl₃
Frequency: 400.40 MHz






134.92
131.35
130.33
129.08
128.27
128.12
126.79

78.15
77.32
77.00
76.68

59.61

38.43





29.69




S151

Vera-RP3-32

Pulse Sequence: DEPT



Solvent: CDCl₃
Frequency: 400.40 MHz



7.81
7.81
7.79
7.79
7.47
7.45
7.40
7.39
7.39
7.38
7.37
7.37
7.30
7.29
7.28
7.27
7.26

4.87
4.86
4.85
4.84

4.19
4.17
4.15
4.13
3.91
3.90
3.87
3.86
3.29
3.28
3.26
3.24
3.13
3.11
3.09
3.08

2.17




7.81
7.81
7.79
7.79


7.47
7.45
7.40
7.39
7.39
7.38
7.37
7.37
7.30
7.29
7.28
7.27
7.26

4.87
4.86
4.85
4.84

4.19
4.17
4.15
4.13
3.91
3.90
3.87
3.86

3.29
3.28
3.26
3.24
3.13
3.11
3.09
3.08





163.68

132.08

131.88

131.41

128.29

128.07

128.06

78.15


77.32

77.00

76.68

59.54



38.63





S154


Vera-RP3-30

Pulse Sequence: DEPT
















Solvent: CDCl₃
Frequency: 400.28 MHz








Vera-RP3-26

Pulse Sequence: DEPT













Solvent: CDCl₃
Frequency: 400.40 MHz





7.85
7.84
7.83
7.82
7.35
7.34
7.33
7.26
7.11
7.09
7.08
7.06
7.05
7.03

4.84
4.84
4.82
4.82
4.81
4.81
4.80
4.16
4.13
4.12
4.09
3.89
3.87
3.85
3.83
3.28
3.27
3.25
3.23
3.06
3.04
3.02
3.01

2.32





S166

Vera-RP3-33

Pulse Sequence: DEPT

